Keros Therapeutics (KROS) Earnings Date & Reports

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

KROS is expected to report earnings to rise 5.26% to -120 cents per share on May 01

Keros Therapeutics KROS Stock Earnings Reports

Q1'25

Est.

$-1.20

Q4'24

Beat

by $0.22

Q3'24

Missed

by $0.13

Q2'24

Beat

by $0.01

Q1'24

Beat

by $0.12

The last earnings report on February 26 showed earnings per share of -113 cents, beating the estimate of -136 cents. With 1.24M shares outstanding, the current market capitalization sits at 416.98M.

View a ticker or compare two or three

Compare

KROS